GENERAL COMMENTARY article

Front. Neurosci., 01 May 2013

Sec. Neuropharmacology

Volume 7 - 2013 | https://doi.org/10.3389/fnins.2013.00069

Erratum: The promise of neuroprotective agents in Parkinson's disease

This article is a commentary on:

  1. The Promise of Neuroprotective Agents in Parkinson’s Disease

    1. Read original article
Stacey E. Seidl Stacey E. Seidl1Judith A. Potashkin* Judith A. Potashkin2*
  • 1The Department of Biological Sciences, DePaul University, Chicago, IL, USA
  • 2The Cellular and Molecular Pharmacology Department, The Chicago Medical School, RFUMS, North Chicago, IL, USA

A commentary on
The promise of neuroprotective agents in Parkinson's disease

by Seidl, S. E., and Potashkin, J. A., (2011). Front. Neurol. 2:68. doi: 10.3389/fneur.2011.00068

After our article was published online, it was brought to our attention that in Table 1 we incorrectly stated the findings from a study testing the safety of Isradipine (Simuni et al., 2010). We have thus changed the text in the table to reflect the results that Isradipine has been shown to be safe and well-tolerated in PD patients.

TABLE 1
www.frontiersin.org

Table 1. Neuroprotective Agents in PD models.

References

Simuni T., Borushko E., Avram M. J., Miskevics S., Martel A., Zadikoff C., et al. (2010). Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov. Disord. 25, 2863–2866.

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

Citation: Seidl SE and Potashkin JA (2013) Erratum: The promise of neuroprotective agents in Parkinson's disease. Front. Neurosci. 7:69. doi: 10.3389/fnins. 2013.00069

Received: 27 March 2013; Accepted: 15 April 2013;
Published online: 01 May 2013.

Edited by:

Nick Andrews, Children's Hospital Boston, USA

Reviewed by:

Anders Haunso, Merck, UK
Zubair Ahmed, University of Birmingham, UK

Copyright © 2013 Seidl and Potashkin. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

*Correspondence:anVkeS5wb3Rhc2hraW5Acm9zYWxpbmRmcmFua2xpbi5lZHU=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.